Related Experiment Video
Updated: Jan 17, 2026
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Synthesis, Computational Analysis, and Pharmacological Evaluation of Novel Schiff Base Hybrids for Anxiolytic and
Amit Kumar1, Sushil Kumar2, Shivam3
1MIT College of Pharmacy, MIT Campus, (Affiliated to Dr. A.P.J. Abdul Kalam Technical University), Ram Ganga Vihar Phase-II, Moradabad, U.P., India.
Introduction:
Schiff bases are a well-known class of substances with a variety of pharmacological properties, including skeletal muscle relaxant and anxiolytic effects. They are ideal candidates for the development of CNS-active drugs due to their structural adaptability and ability to interact with a range of biological targets. The purpose of this study was to create, synthesize, and describe new Schiff base hybrids and assess their possible skeletal muscle relaxant and anxiolytic effects using pharmacological and computational techniques.
Methods:
By using condensation reactions between primary amines and substituted aromatic aldehydes, several new Schiff base hybrids were created. FT-IR, ¹H NMR, ¹³C NMR, and mass spectrometry were used for structural elucidation. To evaluate binding affinity with GABA-A and NMDA receptor sites, computational investigations involving molecular docking and ADME profiling were carried out. Validated rodent models were utilized for pharmacological evaluations, including the rotarod and traction tests to assess skeletal muscle relaxation, as well as the elevated plus maze and open-field tests to evaluate anxiolytic activity.
Results:
The synthesized Schiff base derivatives demonstrated high purity and stability. In accordance with the observed in vivo anxiolytic activity, docking studies demonstrated advantageous binding interactions with the GABA-A receptor.
Discussion:
Certain compounds exhibited moderate skeletal muscle relaxant activity, without producing noticeable sedation or motor impairment, as well as significant anxiolytic effects comparable to those of diazepam (p < 0.05). Good drug-likeness and CNS permeability were predicted for the lead compounds by ADME analysis.
Conclusion:
Both in silico and in vivo tests support the encouraging skeletal muscle relaxant and anxiolytic properties of the synthesized Schiff base hybrids. These results suggest their potential as top contenders for the development of innovative CNS-active medications.
Related Concept Videos
01:29Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
01:28Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...